BioMarin PharmaceuticalMEX:BMRN 80 FCF Yield % is 6.81 as of Jun. 30, 2026, which is 6091% above its 10-year median of 0.11. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,450.39 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,415 Biotechnology companies, BioMarin Pharmaceutical ranks better than 95.55% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
BioMarin Pharmaceutical FCF Yield % Related Terms
BioMarin Pharmaceutical FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BMRN vs CYTK, ARWR, TECH: FCF Yield % Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's FCF Yield % distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (MEX:BMRN) has a FCF Yield % of 6.81 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on BioMarin Pharmaceutical and its competitors. This is 6091% above median its historical median of 0.11. According to the industry distribution chart, BioMarin Pharmaceutical ranks #63 out of 1415 companies in the Biotechnology industry, placing it in the top 4.5%.
Is BioMarin Pharmaceutical's FCF Yield % too high?
BioMarin Pharmaceutical's current FCF Yield % of 6.81 is 6091% above median its 10-year median of 0.11. Based on the distribution chart, BioMarin Pharmaceutical ranks #63 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's FCF Yield % compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #63 out of 1415 companies for FCF Yield %. This places BioMarin Pharmaceutical in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current FCF Yield % is 6.81, which is 6091% above median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,450.39, compared to a current price of MXN959.00 — trading 33.9% below its estimated fair value. The current FCF Yield % is 6.81, which is 6091% above median its 10-year median of 0.11. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current FCF Yield % is 6.81 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of MXN959.00 is trading 33.9% below its estimated GF Value™ of MXN1,450.39.
GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.
Key valuation signals for MEX:BMRN:
FCF Yield %: 6.81 (6091% above median its 10-year median of 0.11)
GF Value™: MXN1,450.39 vs. price of MXN959.00 (33.9% below fair value)
No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score
Get the complete analysis for MEX:BMRN
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BMRN has been successfully added to your 
